Bull J M, Tormey D C, Li S H, Carbone P P, Falkson G, Blom J, Perlin E, Simon R
Cancer. 1978 May;41(5):1649-57. doi: 10.1002/1097-0142(197805)41:5<1649::aid-cncr2820410501>3.0.co;2-j.
A prospective randomized trial was conducted comparing the clinical response of 78 previously untreated patients with advanced metastatic breast cancer to a combination of cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) or to a combination of cyclophosphamide, adriamycin, and 5-fluorouracil (CAF). Sixty-two percent of the patients receiving CMF responded to treatment compared to an 82% response rate for the patients receiving CAF. Although within acceptable limits, hematologic and GI toxicity was greater with CAF. There was no significant difference in the duration of response to the two regimens. Therefore, the therapeutic difference between the two therapies is a higher initial response rate to the adriamycin containing regimen.
进行了一项前瞻性随机试验，比较78例先前未接受治疗的晚期转移性乳腺癌患者对环磷酰胺、甲氨蝶呤和5-氟尿嘧啶（CMF）联合治疗或环磷酰胺、阿霉素和5-氟尿嘧啶（CAF）联合治疗的临床反应。接受CMF治疗的患者中有62%对治疗有反应，而接受CAF治疗的患者的反应率为82%。虽然在可接受范围内，但CAF的血液学和胃肠道毒性更大。两种治疗方案的反应持续时间没有显著差异。因此，两种治疗方法之间的治疗差异在于含阿霉素方案的初始反应率更高。
